Midatech Pharma PLC Investor Webinar

TIDMMTPH

Midatech Pharma PLC

07 September 2020

7 September 2020

Midatech Pharma PLC

("Midatech" or the "Company")

Investor Webinar

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on 10 September 2020, the day of the release of the Company's interim results for the six months ended 30 June 2020.

The webinar can be accessed via: https://webcasting.brrmedia.co.uk/broadcast/5f52278ab14d87262643ee34/5f522da5fa4ec4046427d454

Participants may submit questions during the webinar or in advance via email to:

[e-mail]

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: [phone] 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 James Stearns (Corporate Broking) 
 Tel: [phone] 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker (Corporate Broking) 
  Tel: [phone] 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: [phone] 
 Email: [e-mail] 
 
 Edison Group (US Investor Relations) 
  Megan Paul 
  Tel: [phone] 
  Email: [e-mail] 
           About Midatech Pharma PLC 
            Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
            MTP) is a drug delivery technology company focused on improving 
            the bio-delivery and bio-distribution of medicines. The Company 
            combines approved and development medications with its proprietary 
            and innovative drug delivery technologies to provide compelling 
            products that have the potential to powerfully impact the 
            lives of patients undergoing treatment for life threatening 
            diseases. 
            The Company has developed three in-house technology platforms, 
            each with its own unique mechanism to improve delivery of 
            medications to sites of disease. All of the Company's technologies 
            have successfully entered human use in the clinic, providing 
            important validation of the potential for each platform: 
             *    Q-Sphera(TM) platform: a disruptive micro-technology 
                  used for sustained release to prolong and control the 
                  release of therapeutics over an extended period of 
                  time (from weeks to months). 
 
 
             *    MidaSolve(TM) platform: an innovative nanotechnology 
                  used to dissolve insoluble drugs so that they can be 
                  administered in liquid form directly and locally into 
                  tumours. 
 
 
             *    MidaCore(TM) platform: a leading-edge nanotechnology 
                  used for targeting medications to sites of disease. 
 
 
 
            The platform nature of the technologies allows the potential 
            to develop multiple drug assets rather than being reliant 
            on a limited number of programmes. Midatech's technologies 
            are supported by 36 patent families including 120 granted 
            patents and an additional 70 patent applications. Midatech's 
            headquarters and R&D facility is in Cardiff, UK. For more 
            information please visit www.midatechpharma.com 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

END

NRAEZLFBBKLFBBV

(END) Dow Jones Newswires

September 07, 2020 02:00 ET (06:00 GMT)